Skip to main content
Midas Edge

IOVANCE BIOTHERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

IOVA$8.08-1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share information)

​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · Series A · ​ · Series B · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Convertible · ​ · Convertible · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Accumulated other · ​ · ​ · ​ · ​ · Total
​ · ​ · Preferred Sock · ​ · Preferred Stock · ​ · Common Stock · ​ · Paid-In · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders’
​ · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Income · Deficit · Equity
Balance - January 1, 2021194​$—3,581,119​$4146,874,917​$6​$1,486,662​$19​$(830,193)​$656,498
Stock-based compensation expense​—​​—​—​​—​—​​—​69,765​​—​​—​69,765
Common stock issued upon purchase through employee stock purchase plan​—​​—​—​​—​94,148​​—​​1,586​​—​​—​1,586
Common stock issued upon exercise of stock options​—​​—​—​​—2,822,617​—​33,526​​—​​—​33,526
Common stock sold in public offering, net of offering costs​—​​—​—​​—​6,474,099​​—​​203,155​​—​​—​203,155
Common stock issued from preferred stock conversion​—​​—​(738,961)​​(1)​738,961​​1​​1​​—​​—​1
Unrealized loss on investments​—​​—​—​​—​—​​—​​—​(620)​​—​​(620)
Net loss​—​​—​—​​—​—​​—​​—​​—​(342,252)​​(342,252)
Balance - December 31, 2021194​$—2,842,158​$3157,004,742​$7​$1,794,695​$(601)​$(1,172,445)​$621,659
Stock-based compensation expense​—​​—​—​​—​—​​—​84,022​​—​​—​84,022
Common stock issued upon purchase through employee stock purchase plan​—​​—​—​​—​262,701​​—​​1,655​​—​​—​1,655
Vesting of restricted shares issued for services​—​​—​—​​—894,760​—​—​​—​​—​—
Tax payments related to shares retired for vested restricted stock units​—​​—​—​​—​(342,703)​​—​​(2,649)​​—​​—​(2,649)
Common stock issued upon exercise of stock options​—​​—​—​​—​203,579​​—​​1,642​​—​​—​1,642
Unrealized loss on investments​—​​—​—​​—​—​​—​​—​(301)​​—​​(301)
Common stock sold in public offering, net of offering costs​—​​—​—​​—​29,788,993​​1​​189,501​​—​—​​189,502
Net loss​—​​—​—​​—​—​​—​​—​​—​​(395,893)​​(395,893)
Balance - December 31, 2022194​$—2,842,158​$3187,812,072​$8​$2,068,867​$(902)​$(1,568,338)​$499,638
Stock-based compensation expense​—​​—​—​​—​—​​—​62,625​​—​​—​62,625
Common stock issued upon purchase through employee stock purchase plan​—​​—​—​​—​435,459​​—​​2,410​​—​​—​​2,410
Vesting of restricted shares issued for services​—​​—​—​​—1,253,465​—​—​​—​​—​—
Tax payments related to shares retired for vested restricted stock units​—​​—​—​​—​(454,367)​​—​(2,795)​​—​​—​(2,795)
Common stock sold in public and/or at the market offerings, net of offering costs​—​​—​—​​—​67,080,226​​3​​463,278​​—​​—​​463,281
Common stock issued upon exercise of stock options​—​​—​—​​—8,860​—​63​​—​​—​63
Unrealized gain on investments​—​​—​—​​—​—​​—​​—​940​​—​940
Foreign currency cumulative translation adjustments​​​​​​​​​​​​​​​​​​​​2,488​​—​​2,488
Net loss​—​​—​—​​—​—​​—​​—​​—​(444,037)​(444,037)
Balance - December 31, 2023194​$—2,842,158​$3256,135,715​$11​$2,594,448​$2,526​$(2,012,375)​$584,613
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.